Generic GLP-1s: When Will Prices Fall?

The price of a monthly GLP-1 prescription is one of the loudest barriers to access, and a question follows: when does that change? “Generic GLP-1s” is shorthand for a future where competition drives cost down. That future is coming, but the timeline is governed less by science than by patent law, manufacturing chemistry, and global supply chains.

It helps to separate the older drug from the blockbusters. Liraglutide, an older daily injectable, has already gone generic in the US. Hikma launched a generic of Victoza (liraglutide for type 2 diabetes) in early 2025, and in August 2025 the FDA approved Teva’s generic of Saxenda (liraglutide for weight loss), the first generic GLP-1 ever indicated specifically for weight loss, launched at roughly 30% below the branded price.

Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), the drugs most people actually mean when they say “GLP-1”, are a different story. They remain under layered patent protection. Industry analyses usually place semaglutide’s core US patent expiry around 2031, with formulation and method-of-use patents potentially extending exclusivity further; tirzepatide’s core patents run later still, into the mid-2030s.

Drug	Type	US generic status
Liraglutide (Victoza/Saxenda)	Daily injectable	Generic available (2025)
Semaglutide (Ozempic/Wegovy)	Weekly injectable	Core patent ~2031; later for formulation/use
Tirzepatide (Mounjaro/Zepbound)	Weekly injectable	Core patents into mid-2030s

Why the timeline is messier than a single date

A drug doesn’t have one patent; it has a thicket of them, covering the molecule, the formulation, the dosing device, and the manufacturing process. Even after the core molecule patent expires, secondary patents can delay true generic competition. Litigation over these is routine and hard to predict.

There’s a second complication specific to this drug class. These are not small molecules that a generic maker can synthesize in a simple chemistry vat. They are peptides, manufactured through more involved processes, and several are paired with proprietary injector pens. Reproducing a peptide drug at scale, with consistent purity and stability, is harder and more capital-intensive than copying a small-molecule pill, which raises the bar for a competitor and tends to mean fewer entrants and slower price erosion. The early signal supports this: Teva’s first weight-loss generic launched only about 30% below brand, not the steep discount typical of small-molecule generics.

The honest position: generic liraglutide is already here, but it’s the older daily drug. Meaningful generic competition for semaglutide and tirzepatide, the drugs most people want, is likely years away, and early generics may not be much cheaper at launch.

Forces that could move prices sooner

• Patent expiries by region: timelines differ between the US, Europe, and elsewhere; some markets will see generics earlier.
• Biosimilar-style competition: even partial competition tends to pull list prices down.
• Manufacturing scale-up: as more capacity comes online, the supply-driven scarcity premium eases.
• Payer and policy pressure: negotiated pricing and formulary decisions can lower out-of-pocket cost independent of patents.
• New entrants in the same class: additional branded drugs competing for the same patients add price pressure without a single generic appearing.

The takeaway

Prices will fall, but not on a clean schedule, and probably not all at once. Liraglutide is the early test case: generics arrived in 2024–2025, but at modest discounts. The blockbuster newer drugs, semaglutide and tirzepatide, are protected into the early-to-mid 2030s, and their peptide chemistry makes cheap copies harder than for a typical pill. Expect a gradual decline shaped by patent expiries and growing manufacturing capacity, rather than a sudden cliff. If you’re planning around cost, treat near-term relief as more likely to come from competition between branded drugs and payer negotiation than from true generics of the drug you actually want.

Sources

• FDA approves first generic GLP-1 indicated for weight loss (Teva generic liraglutide, August 2025)
• FDA approves generic GLP-1 medication Victoza (liraglutide) — Hikma (SingleCare)